You are here: Home Welcome H1 Report 2018 MOR106 is an antibody designed to target IL-17C, which potentially plays an important role in skin disorders like AtD. Financial highlights Group revenues €101.9 million Read more Cash position €1066.8 million Read more Letter from the management We have had an incredibly productive first half year 2018. Read more
